Cargando…

Aggressive multiple sclerosis (2): Treatment

The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrambide, Georgina, Iacobaeus, Ellen, Amato, Maria Pia, Derfuss, Tobias, Vukusic, Sandra, Hemmer, Bernhard, Brundin, Lou, Tintore, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412878/
https://www.ncbi.nlm.nih.gov/pubmed/32530366
http://dx.doi.org/10.1177/1352458520924595
_version_ 1783568697428803584
author Arrambide, Georgina
Iacobaeus, Ellen
Amato, Maria Pia
Derfuss, Tobias
Vukusic, Sandra
Hemmer, Bernhard
Brundin, Lou
Tintore, Mar
author_facet Arrambide, Georgina
Iacobaeus, Ellen
Amato, Maria Pia
Derfuss, Tobias
Vukusic, Sandra
Hemmer, Bernhard
Brundin, Lou
Tintore, Mar
author_sort Arrambide, Georgina
collection PubMed
description The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
format Online
Article
Text
id pubmed-7412878
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74128782020-08-19 Aggressive multiple sclerosis (2): Treatment Arrambide, Georgina Iacobaeus, Ellen Amato, Maria Pia Derfuss, Tobias Vukusic, Sandra Hemmer, Bernhard Brundin, Lou Tintore, Mar Mult Scler Meeting Reviews The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS. SAGE Publications 2020-06-12 2020-08 /pmc/articles/PMC7412878/ /pubmed/32530366 http://dx.doi.org/10.1177/1352458520924595 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meeting Reviews
Arrambide, Georgina
Iacobaeus, Ellen
Amato, Maria Pia
Derfuss, Tobias
Vukusic, Sandra
Hemmer, Bernhard
Brundin, Lou
Tintore, Mar
Aggressive multiple sclerosis (2): Treatment
title Aggressive multiple sclerosis (2): Treatment
title_full Aggressive multiple sclerosis (2): Treatment
title_fullStr Aggressive multiple sclerosis (2): Treatment
title_full_unstemmed Aggressive multiple sclerosis (2): Treatment
title_short Aggressive multiple sclerosis (2): Treatment
title_sort aggressive multiple sclerosis (2): treatment
topic Meeting Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412878/
https://www.ncbi.nlm.nih.gov/pubmed/32530366
http://dx.doi.org/10.1177/1352458520924595
work_keys_str_mv AT arrambidegeorgina aggressivemultiplesclerosis2treatment
AT iacobaeusellen aggressivemultiplesclerosis2treatment
AT amatomariapia aggressivemultiplesclerosis2treatment
AT derfusstobias aggressivemultiplesclerosis2treatment
AT vukusicsandra aggressivemultiplesclerosis2treatment
AT hemmerbernhard aggressivemultiplesclerosis2treatment
AT brundinlou aggressivemultiplesclerosis2treatment
AT tintoremar aggressivemultiplesclerosis2treatment
AT aggressivemultiplesclerosis2treatment